Search results
Novartis gets FDA approval of closely watched rare disease drug
BioPharma Dive via Yahoo Finance· 7 months agoDive Brief: The Food and Drug Administration has approved a new Novartis drug for adults with a rare...
Rare Blood Disorder Treatment Breakthrough: Novartis' Candidate Improves Hemoglobin To Near-Normal...
Benzinga via Yahoo Finance· 1 year agoNovartis AG (NYSE: NVS) released detailed results from the Phase 3 APPOINT-PNH trial of...
Could This Be Novartis' Next Blockbuster Medicine?
Motley Fool· 1 year agoLast month, Novartis (NYSE: NVS) revealed encouraging results from a phase 3 clinical trial of the rare-disease drug candidate known as iptacopan for...
Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug
Zacks via Yahoo Finance· 7 months agoNovartis NVS announced that the FDA approved iptacopan as the first oral monotherapy for the...
Novartis' Rare Blood Disorder Therapy Aces Second Late-Stage Trial
Benzinga via Yahoo Finance· 2 years agoNovartis AG's (NYSE: NVS) Phase 3 APPOINT-PNH study of iptacopan in complement-inhibitor-naïve...
Sobi’s Aspaveli obtains indication extension approval in Europe
Pharmaceutical Technology via Yahoo Finance· 1 month agoSobi has received approval for an indication extension from the European Commission for Aspaveli to...
Novartis Experimental Drug Shows Meaningful Superiority Over Previous Treatment In Rare Blood...
Benzinga via Yahoo Finance· 2 years agoNovartis AG's (NYSE: NVS) investigational oral monotherapy iptacopan was superior to anti-C5...
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
Zacks via Yahoo Finance· 6 months agoThis week, AbbVie ABBV announced a definitive agreement to acquire neuroscience drugmaker Cerevel...
Novartis Shares Detailed Results From Experimental Drug For Rare Blood Disorder
Benzinga via Yahoo Finance· 2 years agoNovartis AG (NYSE: NVS) announced detailed results from the pivotal Phase 3 APPLY-PNH trial. The...
AstraZeneca's Blood Clot Treatment Hits Primary Goal In Rare Blood Disorder Trial
Benzinga via Yahoo Finance· 2 years agoAstraZeneca Plc (NASDAQ: AZN) said its Danicopan add-on anti-blood-clotting drug met a primary...